SSC Debate: Backers See Spin-Offs, Foes Cite Priorities

[Editor's note: The recent vote in the U.S. House of Representatives on whether to spend $110 million to start building the superconducting supercollider turned out to be a breeze for proponents of the Texas project (see story on page 2). But even with the outcome of the House vote known, the debate offers a fascinating look at the arguments both sides are expected to use throughout the coming decade as Congress wrestles with funding for the $6 billion accelerator. Supporters, in an effort to bl

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Supporters, in an effort to blunt criticism that the project is merely an expensive toy for a handful of high-Energy physicists, make broad claims for its practical uses, particularly in medicine. They also argue that it is essential to the preservation of U.S. superiority in science. Opponents stress that the project is prone to mismanagement, that it would drain funds from other research fields, and that the government's limited resources would be better spent on small-science projects that are more likely to benefit society.

The question of foreign participation is a sticky one: Both sides would like to see other countries share in the huge cost of the project, but neither side wants the U.S. to sacrifice the technological spin-offs from the SSC.

Following are excerpts from the June 28 House debate on an amendment offered by Rep. Dennis Eckart (D-Ohio) to strip all construction funds from an appropriations bill ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies